Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics

Published: Saturday, June 28, 2014
Last Updated: Saturday, June 28, 2014
Bookmark and Share
Big data approach bridges the gap between genomics and personalized medicine.

Definiens AG which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment said that it has closed a round of financing for € 15 Million. The round was led by Wellington Partners, a leading pan-European venture capital firm.

Gilde Healthcare co-led the financing round and was joined by the other existing investors Cipio Partners and TVM Capital in the financing. In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens' Board of Directors.

The new funds will allow Definiens to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing the company’s Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer.

Tissue Phenomics is based on Definiens' proprietary Cognition Network Technology®, invented by Nobel laureate and founder Prof. Gerd Binnig and involves a unique big data approach to develop new tissue-based diagnostic tests for oncology and immunotherapy.

Using these new diagnostic tests will allow for better prediction of patient outcomes and identification of drug responders, thereby bridging the gap between genomic data and cancer outcomes.

Dr. Rainer Strohmenger, General Partner and Managing Director at Wellington Partners, commented: “We have been following Definiens for many years and have always been impressed by the visionary concept and exciting technology the company has. We believe that Definiens now is approaching an inflection point which will have a significant impact on the growth potential and strategic value of this business for the leading players in imaging, diagnostics and oncology drug development.”

Thomas Heydler, CEO at Definiens, stated: “Wellington Partners is one of the few investors experienced in both diagnostics and healthcare IT with a strong track record of successfully building and capturing value from businesses in these areas. We are honored to add Wellington to our investor base and welcome Dr. Strohmenger to our Board of Directors. This financing will allow us to pursue our aggressive growth strategy to further expand our global leadership in Tissue Phenomics.”

Dr. Gerald Möller, Chairman at Definiens AG, added: “The use of state-of-the-art information technology in medicine will dramatically improve the way patients will be diagnosed and treated and the way new drugs and diagnostic tests will be developed. This change will not only lead to improved patient outcomes but also drive personalized medicine forward, and I am convinced that Definiens will play an important role in accelerating this change, especially in the fields of pathology, cancer, and immunotherapy. The fact that we have attracted this significant financing with new lead investor Wellington is another confirmation of Definiens’ strong position.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens and Bioscan Team Up for Cooperative Marketing Efforts
Under the terms of the agreement, the companies will offer integrated solutions for intelligent small animal imaging analysis.
Wednesday, December 03, 2008
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!